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TGZS is produced mainly by SULT1A1 in the liver, and predominantly excreted into the bile (Kawai et al., 1997; Honma et al., 2002 et al., 2000) . As far as hepatic uptake is concerned, Nozawa et al. (2004) demonstrated that TGZS is transported by OATP1B1 and OATP1B3, and OATP1B1 transported TGZS more efficiently than OATP1B3 (Nozawa et al., 2004 ). OATP1B1 will play major role in the hepatic uptake of TGZS. As far as the biliary excretion process is concerned, Kostrubsky et al.
investigated the involvement of multidrug resistance associated protein 2 (MRP2/ABCC2) in the biliary excretion of TGZS using TR -rats, a mutant strain with an inherited deficiency in MRP2.
The biliary excretion of TGZS was delayed in TR -rats compared with normal rats, however, the amount of TGZS excreted into the bile was not markedly reduced in TR -rats (Kostrubsky et al.,
replacing the medium on one side of the cell monolayer with Krebs-Henseleit buffer containing 3 µM TGZS. At appropriate times (1, 2 and 3 h), 100 µL aliquots were taken from the opposite side of the cell monolayer and replaced with 100 µL buffer. After the last sampling, the cell monolayers were solubilized with 500 µL 0.2 M NaOH, and then neutralized with 100 µL 1 M HCl. The protein concentration was measured by the Lowry method.
The flux of TGZS across cell monolayers was calculated as follows, 8 samples (1 µL) were mixed with 49 µL PBS and 100 µL acetonitrile and the liver homogenates (10 µL) were mixed with 40 µL PBS and 100 µL acetonitrile. All these mixed solutions were centrifuged at 15,000 xg for 10 min. The supernatants (plasma sample; 80 µL, bile and liver sample; 10 µL) were evaporated and the pellets were reconstituted with 20% acetonitrile (plasma sample; 80 µL, bile and liver sample; 200 µL) and subjected to LC/MS analysis.
Determination of urinary excretion of TGZS in wild-type and Bcrp (-/-) mice
Under urethane anesthesia (1.25 g/kg, i.p.), the right jugular vein was cannulated with a polyethylene tube (PE-10) for injection of TGZS and the urinary bladder was cannulated with two polyethylene tubes (PE-50; Becton Dickinson). One cannula was fitted with a syringe filled with saline to wash the inside of the urinary bladder and the other cannula was used for the collection of urine and wash solution. TGZS was injected at a dose of 0.5 µmol/kg followed by continuous infusion at a dose rate of 0.1 µmol/h/kg. Mannitol was concomitantly infused at a dose rate of 160 mg/h/kg to increase the urine volume. Urine samples were collected at 20 min intervals between 60 and 120 min. Following every collection of urine, the bladder was flushed with about 300 µL saline and the wash solution was added to the urine.
The urine samples (50 µL) were mixed with 150 µL acetonitrile and centrifuged at 15,000 xg for 10 min. The supernatants (100 µL) were evaporated and the pellets were reconstituted in
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In vivo biliary excretion study
Because the plasma and biliary excretion was almost constant between 60 to 120 min (Figure 3) , the plasma and liver concentrations at 120 min were assumed to be steady-state concentrations. Total clearance (CLtot) was calculated by dividing the infusion rate by the plasma concentration at 120 min. The biliary excretion clearance based on the plasma concentration (CL bile,plasma ) was calculated by dividing the biliary excretion rate in the last time segment (100 -120 min) by the plasma concentration at 120 min. The biliary excretion clearance based on the liver concentration (CL bile,liver ) was calculated by dividing the biliary excretion rate in the last time segment by the liver concentration at 120 min. The fraction of the biliary excretion was calculated by dividing the biliary excretion rate in the last time segment by the infusion rate.
Efflux transport in everted sac study
The mucosally excreted amounts of TGZS per unit length of tissue were calculated as follows,
1 1 probability of <0.05 was considered to be statistically significant.
Results

In vitro transport study of TGZS in BCRP expressed cells
BCRP-mediated transport of TGZS was examined using GFP, mBcrp and hBCRP expressed MDCKII/OATP1B1 cells. Figure 2 shows the time-courses of the transcellular transport of TGZS in GFP, mBcrp and hBCRP expressed cell systems. The transport of TGZS increased linearly up to 3 h, suggesting that the initial rates were maintained up to the end of the experiments. The transport rates are summarized in Table 1 . The apical-to-basal transport was significantly reduced in hBCRP expressed cells compared with that in GFP cells. The basal-to-apical transport was significantly increased in both mBcrp and hBCRP expressed cells.
The ratios of basal-to-apical / apical-to-basal flux were 3.6 and 9.3, in MDCK II cells expressing OATP1B1/mBcrp and OATP1B1/hBCRP, respectively, whereas that in GFP expressed cells was almost symmetric (flux ratio was 1.45).
Effect of BCRP on the biliary excretion of TGZS
The biliary excretion study was performed by continuous infusion with a priming dose to achieve steady-state conditions. The biliary excretion, plasma and liver concentrations of
1 2 excretion clearances based on the plasma and liver concentrations were markedly reduced in Bcrp (-/-) mice, to about 30% of those in wild-type mice. The biliary excretion of TGZS was almost 100% in wild-type mice, while that in Bcrp (-/-) mice was 32.6%. These results indicate that there is another elimination process for TGZS in Bcrp (-/-) mice. To investigate this, the urinary excretion of TGZS was examined in Bcrp (-/-) mice. However, TGZS concentrations in all the urine samples were below the lower limit of quantification (10 nM).
Because the volume of the urine sample (urine + wash solution) was less than 450 µL at every 20 min period, the urinary excretion rate of TGZS was considered to be less than 0.45 nmol/h/kg. This means that the urinary excretion of TGZS is less than 1 % of the dose in Bcrp (-/-) mice.
Effect of BCRP on the mucosal efflux transport of TGZS in everted sacs
The effect of BCRP on the mucosal efflux transport of TGZS was examined by using everted ileum sacs. TGZ was added to the mucosal side, and the mucosal efflux of the intracellularly formed TGZS was determined. The results are shown in demonstrated the cholestatic effect of TGZ in rats (Funk et al., 2001b) . In that report, the plasma and liver concentrations of TGZS were 110 and 260 µM, respectively, much higher than those in the present study (plasma; 0.1-0.2 µM, liver; 10-15 µM). This suggests that the plasma and liver concentrations of TGZS in the present study were too low to induce cholestasis.
Comparison of the total body and biliary excretion clearances showed that biliary excretion is the main elimination pathway of TGZS in wild-type mice. The biliary excretion of TGZS was markedly reduced in Bcrp (-/-) mice, and CL bile,liver , which represents the intrinsic efflux ability at the canalicular membrane, was reduced in Bcrp (-/-) mice to 29% of that in wild-type mice. Therefore, BCRP is the major transporter involved in the biliary excretion of TGZS. Cumulative studies using Mrp2-deficient mutant rats have shown that MRP2 accounts for the biliary excretion of some sulfate conjugates, such as tauro-conjugated bile acid sulfate, phenolphthalein sulfate and acetaminophen sulfate (Takikawa et al., 1991; Akimoto et al., 2001; Tanaka et al., 2003; Zamek-Gliszczynski et al., 2005 The total clearance and hepatic concentration were not changed in Bcrp (-/-) mice although biliary excretion is the predominant elimination pathway in wild-type mice. At steady-state, the biliary excretion accounts for, at most, 30% of the total body clearance in Bcrp (-/-) mice, and the remaining fraction could be explained by other elimination mechanisms that were induced to compensate for the loss of biliary excretion. Urinary excretion could be an alternative elimination pathway of TGZS. However, the urinary excretion of TGZS was negligible in Bcrp (-/-) mice. Therefore, induction of hepatic metabolic enzymes is a likely mechanism. Currently, there is no information regarding the enzymes that are induced in Bcrp (-/-) mice, and further studies are necessary to identify them.
The effect of BCRP on the intestinal re-absorption was examined using everted ileum The C376T mutation introduces a stop codon, resulting in the production of truncated BCRP (Imai et al., 2002) . The C421A allele is associated with a reduction in the protein level (Imai et al., 2002; Kondo et al., 2004; Kobayashi et al., 2005) . The G1322A allele affects both the protein level and localization of BCRP (Kondo et al., 2004) . Among these SNPs, C421A
exhibits the highest frequency (about 10% and 30% in Caucasian and Japanese, respectively) (Kobayashi et al., 2005) . Clinical studies revealed that the plasma exposure of diflomotecan, topotecan and rosuvastatin was higher in subjects carrying the C421A allele (Sparreboom et al., 2004; Sparreboom et al., 2005) . These functional SNPs of BCRP may increase the liver and/or plasma exposure of TGZS, affecting the susceptibility to TGZS if any induction of compensatory mechanisms, which were observed in Bcrp (-/-) mice, do not occur in humans.
Besides BCRP, SULT1A1 and OATP1B1 also have functional SNPs (Raftogianis et al., 1997; Nowell et al., 2002; Nishizato et al., 2003; Mwinyi et al., 2004; Wegman et al., 2005; Maeda et al., 2006) . A combination of these functional SNPs in BCRP, SULT1A1 and OATP1B1 may be involved in the idiosyncratic hepatotoxicity of TGZ.
In conclusion, our present study revealed that TGZS is a substrate of mBcrp and hBCRP, and that the biliary excretion of TGZS is mainly mediated by BCRP in mice. 
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